Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula (Q34422110)

2 August 2017

title

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. (English)

1 reference

2 August 2017

1 reference

1 reference

Aude Bonehill

6

0 references

Karine Breckpot

object named as

Karine Breckpot

5

0 references

Kris Thielemans

8

object named as

Kris Thielemans

1 reference

2 August 2017

Sandra Van Lint

1

1 reference

2 August 2017

Sofie Wilgenhof

2

1 reference

2 August 2017

Carlo Heirman

3

1 reference

2 August 2017

Jurgen Corthals

4

1 reference

2 August 2017

Bart Neyns

7

1 reference

2 August 2017

publication date

31 May 2014

1 reference

Cancer Immunology, Immunotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

63

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

959-967

1 reference

Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Trial watch: Dendritic cell-based interventions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Trial watch: Dendritic cell-based interventions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Dendritic cells in tolerance induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Migration of dendritic cell based cancer vaccines: in vivo veritas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

CD27 and CD70 in T cell and B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Characterization of the ribonuclease activity on the skin surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Tumor vaccination using messenger RNA: prospects of a future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

RNA vaccines in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

mRNA as a versatile tool for exogenous protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Targeting the tumor mutanome for personalized vaccination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Exploiting the mutanome for tumor vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

The regulatory landscape for actively personalized cancer immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1558-3

10.1007/S00262-014-1558-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1010532242

0 references

1 reference